Disease Control in Progressive Pancreatic and Intestinal Neuroendocrine Tumors by Combined Treatment with Lanreotide Autogel and Temozolomide: The SONNET Study

Pavel ME, Denecke T, Lahner H, Hoersch D, Rinke A, Koch A, Liyanage N, Raspel A, Pape UF, Raderer M (2018)

Publication Type: Conference contribution

Publication year: 2018

Journal

Neuroendocrinology Karger

Book Volume: 106

Pages Range: 202-202

Authors with CRIS profile

Marianne Ellen Pavel Professur für Endokrinologie

Involved external institutions

Vienna General Hospital / Allgemeines Krankenhaus der Stadt Wien (AKH)

Austria (AT) Universitätsklinikum Essen

Germany (DE) Universitätsklinikum Gießen und Marburg (UKGM)

Germany (DE) Freie Universität Berlin

Germany (DE) Ipsen Pharma GmbH

Germany (DE) Ipsen Pharma

France (FR) Zentralklinikum Bad Berka

Germany (DE)

How to cite

APA:

Pavel, M.E., Denecke, T., Lahner, H., Hoersch, D., Rinke, A., Koch, A.,... Raderer, M. (2018). Disease Control in Progressive Pancreatic and Intestinal Neuroendocrine Tumors by Combined Treatment with Lanreotide Autogel and Temozolomide: The SONNET Study. (pp. 202-202).

MLA:

Pavel, Marianne Ellen, et al. "Disease Control in Progressive Pancreatic and Intestinal Neuroendocrine Tumors by Combined Treatment with Lanreotide Autogel and Temozolomide: The SONNET Study." 2018. 202-202.

BibTeX: Download